Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-04-16

FDA Approved: EDARBYCLOR — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))

View source ↗

Summary

FDA approved a supplemental application for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE) submitted by Azurity Pharmaceuticals (formerly Arbor Pharmace…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)

Snippet

SUPPL AP for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)